CBLO 最新10-Q变化
将 CBLO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-20 与上一份 10-Q · 2026-02-20
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +66 | −49 | ~34 | 66 |
| 市场风险(第3项) | 文字有新增/删除 | +66 | −49 | ~34 | 65 |
| 控制与程序 | 文字有新增/删除 | +66 | −49 | ~34 | 65 |
| 法律诉讼 | 文字有新增/删除 | +66 | −49 | ~34 | 65 |
| 风险因素 | 文字有新增/删除 | +66 | −49 | ~34 | 65 |
| 其他信息 | 文字有新增/删除 | +66 | −49 | ~34 | 64 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议